Tolsma TO, Hansen JC. Post-translational modifications and chromatin dynamics. Essays Biochem. 2019;63:89–96.

Article  PubMed  Google Scholar 

Narita T, Weinert BT, Choudhary C. Functions and mechanisms of non-histone protein acetylation. Nat Rev Mol Cell Biol. 2019;20:156–74.

Article  PubMed  Google Scholar 

Lavoie H, Gagnon J, Therrien M. ERK signalling: a master regulator of cell behaviour, life and fate. Nat Rev Mol Cell Biol. 2020;21:607–32.

Article  PubMed  Google Scholar 

González A, Hall MN, Lin S-C, Hardie DG. AMPK and TOR: the yin and yang of cellular nutrient sensing and growth control. Cell Metab. 2020;31:472–92.

Article  PubMed  Google Scholar 

Michalak EM, Burr ML, Bannister AJ, Dawson MA. The roles of DNA, RNA and histone methylation in ageing and cancer. Nat Rev Mol Cell Biol. 2019;20:573–89.

Article  PubMed  Google Scholar 

Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9:153–66.

Article  PubMed  Google Scholar 

Gupta R, Sahu M, Srivastava D, Tiwari S, Ambasta RK, Kumar P. Post-translational modifications: regulators of neurodegenerative proteinopathies. Ageing Res Rev. 2021;68:101336.

Article  PubMed  Google Scholar 

Cohen P, Cross D, Jänne PA. Kinase drug discovery 20 years after imatinib: progress and future directions. Nat Rev Drug Discov. 2021;20:551–69.

Article  PubMed  PubMed Central  Google Scholar 

Wang Y, Xie Q, Tan H, Liao M, Zhu S, Zheng LL, et al. Targeting cancer epigenetic pathways with small-molecule compounds: therapeutic efficacy and combination therapies. Pharmacol Res. 2021;173:105702.

Article  PubMed  Google Scholar 

Deng L, Meng T, Chen L, Wei W, Wang P. The role of ubiquitination in tumorigenesis and targeted drug discovery. Signal Transduct Target Ther. 2020;5:1–28.

Article  Google Scholar 

Ochoa D, Jarnuczak AF, Viéitez C, Gehre M, Soucheray M, Mateus A, et al. The functional landscape of the human phosphoproteome. Nat Biotechnol. 2020;38:365–73.

Article  PubMed  Google Scholar 

Weinert BT, Narita T, Satpathy S, Srinivasan B, Hansen BK, Schölz C, et al. Time-resolved analysis reveals rapid dynamics and broad scope of the CBP/p300 acetylome. Cell. 2018;174:231–44.

Article  PubMed  PubMed Central  Google Scholar 

Dai Vu L, Gevaert K, De Smet I. Protein language: post-translational modifications talking to each other. Trends Plant Sci. 2018;23:1068–80.

Article  Google Scholar 

Wu Z, Huang R, Yuan L. Crosstalk of intracellular post-translational modifications in cancer. Arch Biochem Biophys. 2019;676:108138.

Article  PubMed  Google Scholar 

Kim MS, Pinto SM, Getnet D, Nirujogi RS, Manda SS, Chaerkady R, et al. A draft map of the human proteome. Nature. 2014;509:575–81.

Article  PubMed  PubMed Central  Google Scholar 

Wilhelm M, Schlegl J, Hahne H, Gholami AM, Lieberenz M, Savitski MM, et al. Mass-spectrometry-based draft of the human proteome. Nature. 2014;509:582–7.

Article  PubMed  Google Scholar 

Xu JY, Zhang C, Wang X, Zhai L, Ma Y, Mao Y, et al. Integrative proteomic characterization of human lung adenocarcinoma. Cell. 2020;182:245–61.

Article  PubMed  Google Scholar 

Vasaikar S, Huang C, Wang X, Petyuk VA, Savage SR, Wen B, et al. Proteogenomic analysis of human colon cancer reveals new therapeutic opportunities. Cell. 2019;177:1035–49.e19

Article  PubMed  PubMed Central  Google Scholar 

Mertins P, Mani DR, Ruggles KV, Gillette MA, Clauser KR, Wang P, et al. Proteogenomics connects somatic mutations to signalling in breast cancer. Nature. 2016;534:55–62.

Article  PubMed  PubMed Central  Google Scholar 

Gao Q, Zhu H, Dong L, Shi W, Chen R, Song Z, et al. Integrated proteogenomic characterization of hbv-related hepatocellular carcinoma. Cell. 2019;179:561–77.

Article  PubMed  Google Scholar 

Clark DJ, Dhanasekaran SM, Petralia F, Pan J, Song X, Hu Y, et al. Integrated proteogenomic characterization of clear cell renal cell carcinoma. Cell. 2019;179:964–83.

Article  PubMed  PubMed Central  Google Scholar 

Zhang H, Liu T, Zhang Z, Payne SH, Zhang B, McDermott JE, et al. Integrated proteogenomic characterization of human high-grade serous ovarian cancer. Cell. 2016;166:755–65.

Article  PubMed  PubMed Central  Google Scholar 

Huang C, Chen L, Savage SR, Eguez RV, Dou Y, Li Y, et al. Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma. Cancer Cell. 2021;39:361–79.

Article  PubMed  PubMed Central  Google Scholar 

Keretsu S, Ghosh S, Cho SJ. Molecular modeling study of c-KIT/PDGFR alpha dual inhibitors for the treatment of gastrointestinal stromal tumors. Int J Mol Sci. 2020;21:8232.

Ng YLD, Ramberger E, Bohl SR, Dolnik A, Steinebach C, Conrad T, et al. Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma. Nat Commun. 2022;13:1009.

Article  PubMed  PubMed Central  Google Scholar 

Senisterra GA, Markin E, Yamazaki K, Hui R, Vedadi M, Awrey DE. Screening for ligands using a generic and high-throughput light-scattering-based assay. J Biomol Screen. 2006;11:940–8.

Article  PubMed  Google Scholar 

Martinez Molina D, Jafari R, Ignatushchenko M, Seki T, Larsson EA, Dan C, et al. Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science. 2013;341:84–7.

Article  PubMed  Google Scholar 

Lomenick B, Hao R, Jonai N, Chin RM, Aghajan M, Warburton S, et al. Target identification using drug affinity responsive target stability (DARTS). Proc Natl Acad Sci USA. 2009;106:21984–9.

Article  PubMed  PubMed Central  Google Scholar 

Feng Y, De Franceschi G, Kahraman A, Soste M, Melnik A, Boersema PJ, et al. Global analysis of protein structural changes in complex proteomes. Nat Biotechnol. 2014;32:1036–44.

Article  PubMed  Google Scholar 

Savitski MM, Reinhard FB, Franken H, Werner T, Savitski MF, Eberhard D, et al. Tracking cancer drugs in living cells by thermal profiling of the proteome. Science. 2014;346:1255784.

Article  PubMed  Google Scholar 

Franken H, Mathieson T, Childs D, Sweetman GM, Werner T, Togel I, et al. Thermal proteome profiling for unbiased identification of direct and indirect drug targets using multiplexed quantitative mass spectrometry. Nat Protoc. 2015;10:1567–93.

Article  PubMed  Google Scholar 

Knockaert M, Wieking K, Schmitt S, Leost M, Grant KM, Mottram JC, et al. Intracellular targets of paullones. identification following affinity purification on immobilized inhibitor. J Biol Chem. 2002;277:25493–501.

Article  PubMed  Google Scholar 

Bantscheff M, Eberhard D, Abraham Y, Bastuck S, Boesche M, Hobson S, et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol. 2007;25:1035–44.

Article  PubMed  Google Scholar 

Klaeger S, Heinzlmeir S, Wilhelm M, Polzer H, Vick B, Koenig PA, et al. The target landscape of clinical kinase drugs. Science. 2017;358:eaan4368.

Pawson T, Scott JD. Protein phosphorylation in signaling–50 years and counting. Trends Biochem Sci. 2005;30:286–90.

Article  PubMed  Google Scholar 

Mann M, Ong SE, Gronborg M, Steen H, Jensen ON, Pandey A. Analysis of protein phosphorylation using mass spectrometry: deciphering the phosphoproteome. Trends Biotechnol. 2002;20:261–8.

Article  PubMed  Google Scholar 

Krueger KE, Srivastava S. Posttranslational protein modifications: current implications for cancer detection, prevention, and therapeutics. Mol Cell Proteom. 2006;5:1799–810.

Article  Google Scholar 

Singh V, Ram M, Kumar R, Prasad R, Roy BK, Singh KK. Phosphorylation: implications in cancer. Protein J. 2017;36:1–6.

Article  PubMed  Google Scholar 

Attwood MM, Fabbro D, Sokolov AV, Knapp S, Schioth HB. Trends in kinase drug discovery: targets, indications and inhibitor design. Nat Rev Drug Discov. 2021;20:839–61.

Article  PubMed  Google Scholar 

Krautkramer KA, Reiter L, Denu JM, Dowell JA. Quantification of SAHA-dependent changes in histone modifications using data-independent acquisition mass spectrometry. J Proteome Res. 2015;14:3252–62.

Article  PubMed  PubMed Central  Google Scholar 

Cutillas PR. Role of phosphoproteomics in the development of personalized cancer therapies. Proteom Clin Appl. 2015;9:383–95.

Article  Google Scholar 

Capra M, Nuciforo PG, Confalonieri S, Quarto M, Bianchi M, Nebuloni M, et al. Frequent alterations in the expression of serine/threonine kinases in human cancers. Cancer Res. 2006;66:8147–54.

Article  PubMed  Google Scholar 

Phadke M, Remsing Rix LL, Smalley I, Bryant AT, Luo Y, Lawrence HR, et al. Dabrafenib inhibits the growth of BRAF-WT cancers through CDK16 and NEK9 inhibition. Mol Oncol. 2018;12:74–88.

Article  PubMed